WOBURN, Mass.--(BUSINESS WIRE)--Excelimmune, Inc. announced today they have received a $1 million investment as part of an open Series-B financing round. The investment comes from a mixture of existing and new investors. Proceeds from the financing will be used to continue studies of the company’s first drug candidate, Staphguard, a human recombinant polyclonal antibody (HRPA) against methicillin-resistant Staphylococcus aureus (MRSA). In September 2009, Excelimmune was awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH) to develop a HRPA against Clostridium difficile.
